Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...
In the assessment of 12-month price targets, analysts unveil insights for Kenvue, presenting an average target of $24.1, a ...
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...
Kenvue, Inc. (KVUE – Research Report), the Technology sector company, was revisited by a Wall Street analyst yesterday. Analyst Anna ...
Kenvue shares jumped premarket after The Wall Street Journal reported that Starboard Value has taken a sizable stake in the ...
Recent health news includes a court ruling allowing Amgen's Eylea biosimilar launch, Starboard criticizing Kenvue's skin ...
Activist investor Starboard Value reportedly has taken a large stake in consumer health products maker Kenvue.
Shares of consumer-products company Kenvue Inc. rose the most in two months after the Wall Street Journal reported that ...
J.P. Morgan analyst Andrea Faria Teixeira has maintained their bullish stance on KVUE stock, giving a Buy rating on October 15. Andrea Faria ...
By Svea Herbst-Bayliss (Reuters) -Hedge fund Starboard Value called consumer products company Kenvue a bargain and said its ...
Financial writer highlights activist investor Starboard Value's push for Kenvue (KVUE) to divest its challenged skin, ...